Veru publishes presentation on enobosarm in older patients with obesity
VERU•
VERU•Veru published an Obesity Week presentation detailing a post hoc analysis of enobosarm in semaglutide-treated patients aged 65 or older. Over 16 weeks, lean mass rose 0.3 kg with enobosarm versus a 2 kg decline with placebo; the presentation also outlined a fully enrolled 239-patient Phase 2b trial.
In the 16-week analysis, lean mass rose 0.3 kg with enobosarm 3 mg, compared with a 2 kg decline with placebo (p=0.0001). Among 26 patients per arm, no enobosarm recipients lost at least 10% of stair-climbing power, versus 42% on placebo. Between-group differences in stair-climbing time and power were not statistically significant, with p-values of 0.056 and 0.065, respectively.
The presentation outlined the fully enrolled Phase 2b PLATEAU trial, which is testing enobosarm 3 mg in 239 older patients over 68 weeks.